“…Upon knockdown (e.g., with siRNA), triple-negative breast cancer (TNBC) and basal bladder cancers exhibit decreased proliferation and invasion properties. , Unfortunately, studies with small-molecule inhibitors of c-Src (including: dasatinib, bosutinib, and ponatinib) failed to recapitulate the strong anticancer phenotype observed from genetic knockdown of c-Src and were not successful in the clinic. , Many noncatalytic functions have been reported for c-Src, typically involving protein–protein interaction between a partner protein and c-Src’s SH2 and SH3 domains. , Several binding partners of c-Src have been identified, including epidermal growth factor receptors, focal adhesion kinase, and hormone receptors . In TNBC, c-Src’s SH2 domain has been shown to be important for tumorigenicity . PROTACs provide a means of chemical knockdown that will prevent both catalytic and noncatalytic functions, and we were thus interested in developing a PROTAC for c-Src.…”